Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Sees CRM Pipeline Aiding ICD Market Share Gains

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific is highlighting recent and near-term product introductions as a key component of its plan to boost market share in its cardiac rhythm management business

You may also be interested in...



New CRM launches

Boston Scientific announces CE-mark approval of the Cognis cardiac resynchronization therapy defibrillator (CRT-D) and the Teligent ICD Jan. 22. The company says the devices, for which a full rollout in international markets is planned in the second quarter, are among the smallest and thinnest implantable defibrillators available, at 32.5 cc and 31.5 cc, respectively. Both products are pending FDA approval, with a U.S. launch expected in the second half of 2008, the firm says (1"The Gray Sheet" Oct. 29, 2007, p. 16)

New CRM launches

Boston Scientific announces CE-mark approval of the Cognis cardiac resynchronization therapy defibrillator (CRT-D) and the Teligent ICD Jan. 22. The company says the devices, for which a full rollout in international markets is planned in the second quarter, are among the smallest and thinnest implantable defibrillators available, at 32.5 cc and 31.5 cc, respectively. Both products are pending FDA approval, with a U.S. launch expected in the second half of 2008, the firm says (1"The Gray Sheet" Oct. 29, 2007, p. 16)

St. Jude Medical: Competitor’s Recall Clouds ICD Market Predictions

St. Jude Medical believes it is well positioned to continue increasing its share of the implantable cardioverter defibrillator market in 2008, even though it is too soon to predict the precise impact of competitor Medtronic's Sprint Fidelis ICD lead recall

Related Content

UsernamePublicRestriction

Register

MT025409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel